Subscribe To
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
User Fee Goal Date: October 17, 2023 WALTHAM, Mass., May 17, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of […] The post Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XP...
Read More
Content Topics
Ardelyx
Announces
Acceptance
Six
Month
Review
Resubmission
Six month
Application
Xphozah
tenapanor
Forex
Posted: May 17 2023, 11:30
Author Name: forextv
Views: 102065